Welcome to our dedicated page for Supernus Pharma news (Ticker: SUPN), a resource for investors and traders seeking the latest updates and insights on Supernus Pharma stock.
Supernus Pharmaceuticals (SUPN) is a leading biopharmaceutical innovator focused on developing advanced treatments for central nervous system disorders. This dedicated news hub provides investors and healthcare professionals with timely updates on the company's clinical developments, regulatory milestones, and strategic initiatives in neurology and psychiatry.
Access comprehensive coverage of SUPN's progress in treating epilepsy, ADHD, and movement disorders through reformulated therapeutics. Our curated news feed includes updates on FDA submissions, partnership announcements, clinical trial results, and market expansion efforts – all essential for understanding the company's position in CNS therapeutics.
Key areas of focus include non-stimulant ADHD treatments, extended-release neurology medications, and novel approaches to Parkinson's-related conditions. Stay informed about SUPN's pipeline advancements and commercial strategies through verified press releases and objective analysis.
Bookmark this page for direct access to Supernus Pharmaceuticals' latest developments in neuroscience innovation. Check regularly for updates on product approvals, research collaborations, and financial performance indicators relevant to CNS treatment advancements.
Holly Robinson Peete and her daughter Ryan are collaborating with Supernus Pharmaceuticals to enhance awareness about Attention-deficit/Hyperactivity Disorder (ADHD) during ADHD Awareness Month. With ADHD affecting 6.1 million U.S. children, Peete aims to reduce stigma and promote understanding of the condition. Supernus Pharmaceuticals supports this initiative, emphasizing the importance of recognizing ADHD's symptoms and encouraging families to seek treatment. The partnership offers resources at MoreToADHD.com for those affected by the disorder.
Supernus Pharmaceuticals announced its agreement to acquire Adamas Pharmaceuticals for $8.10 per share in cash, totaling approximately $400 million. The deal includes contingent value rights that could raise the total to $9.10 per share, based on sales milestones of GOCOVRI. This acquisition is strategically significant as it strengthens Supernus's Parkinson's disease portfolio with two FDA-approved products, GOCOVRI and Osmolex ER, and is expected to generate $60 million to $80 million in synergies in the first year. The transaction is projected to close in Q4 2021 or Q1 2022.
Supernus Pharmaceuticals (Nasdaq: SUPN) announced that the FDA has accepted its supplemental new drug application for Qelbree (viloxazine extended-release capsules) aimed at treating ADHD in adults. The sNDA's user fee goal date is set for April 29, 2022. A Phase III study previously showed significant efficacy and tolerability of Qelbree in adult patients. Qelbree, already approved for pediatric use, represents a new treatment option for approximately 10 million adults with ADHD in the U.S., according to CEO Jack Khattar.
Supernus Pharmaceuticals, focused on CNS disease treatments, will participate in three key virtual investor conferences in September 2021.
- Citi’s 16th Annual BioPharma Virtual Conference: September 9, 2021, one-on-one meetings.
- Wells Fargo 2021 Virtual Healthcare Conference: September 10, 2021, presentation at 9:20 a.m. ET.
- Morgan Stanley 19th Annual Global Healthcare Conference: September 15, 2021, fireside chat at 11:45 a.m. ET.
Webcasts available on their website post-conference.
Supernus Pharmaceuticals reported second quarter 2021 revenues of $141.3 million, a 12% increase from the previous year. The launch of Qelbree for pediatric ADHD saw net product sales of $0.3 million. Operating earnings were $34.1 million, down from $45.5 million in 2020. Net earnings and diluted EPS were $23.7 million and $0.43, respectively, compared to $34.7 million and $0.65 a year prior. The company has $855.3 million in cash as of June 30, 2021. Financial guidance for the full year remains unchanged at $550 - $580 million in total revenues.
Supernus Pharmaceuticals (Nasdaq: SUPN) announced it will report its second quarter 2021 financial results on August 4, 2021, after market close. A conference call will be held on the same day at 4:30 p.m. ET, led by CEO Jack Khattar and CFO Jim Kelly, to discuss these results. Attendees can join via dial-in or a live webcast on the company’s website. Supernus specializes in developing treatments for central nervous system diseases and has a diverse portfolio that includes approved medications for conditions like epilepsy and Parkinson's disease.
Supernus Pharmaceuticals (Nasdaq: SUPN) announced that CEO Jack Khattar will present a company overview at the Jefferies Virtual Healthcare Conference on June 1, 2021, at 1:30 p.m. ET. Interested parties can access the live webcast via the company’s Investor Relations page. An archived replay will be available for 60 days post-conference.
Supernus focuses on treatments for central nervous system (CNS) diseases, including epilepsy, migraine, and ADHD among others.
Supernus Pharmaceuticals has announced the availability of its FDA-approved ADHD treatment, Qelbree (viloxazine extended-release capsules), for pediatric patients aged 6 to 17. This non-stimulant medication has shown efficacy in improving ADHD symptoms as early as the first week of treatment. Alongside its launch, Supernus has implemented comprehensive patient support programs, including co-pay assistance and a sampling initiative. The company plans to submit a supplemental New Drug Application for Qelbree's use in adults in Q3 2021.
Supernus Pharmaceuticals (SUPN) reported Q1 2021 total revenues of $130.9 million, a 38% increase from Q1 2020. Net product sales totaled $128.4 million, up 39% year-over-year, driven by Trokendi XR and Oxtellar XR. The FDA approved Qelbree for pediatric ADHD, with a planned launch in Q2 2021 and an sNDA for adults anticipated in Q3 2021. Operating earnings were $13.2 million, down from $29.0 million in the previous year. The company has $807.7 million in cash and reiterates its full-year revenue guidance of $550 - $580 million.
Supernus Pharmaceuticals (Nasdaq: SUPN) has reported that Newron Pharmaceuticals has received a Paragraph IV Notice Letter from Aurobindo Pharma regarding its application for safinamide tablets. This letter targets three XADAGO patents expiring between June 2027 and December 2028. Supernus holds a license agreement with Zambon S.p.A. concerning these patents. The company is reviewing the Notice Letter details to safeguard its intellectual property rights related to XADAGO, which is under FDA exclusivity until March 21, 2022.
FAQ
What is the current stock price of Supernus Pharma (SUPN)?
What is the market cap of Supernus Pharma (SUPN)?
